Licensing and option agreement
Activaero GmbH, specialist in inhalation products and systems, has signed a licensing and option agreement with Bayer HealthCare AG for the development of inhaled treatments.
The deal includes an upfront payment for Activaero, which is a spin-off from the Helmholtz Zentrum München, as well as the potential for milestone payments.
Dr Gerhard Scheuch, founder and CEO of Activaero said: “This licensing deal represents a major milestone for Activaero and together with our scientific team, we look forward to supporting Bayer HealthCare throughout the upcoming development.
"We believe that pulmonary administration of drugs has a huge potential for the treatment of lung diseases and diseases which start in the lung. With this in mind, it will be exciting to develop innovative therapies with Bayer HealthCare, a worldwide leader in the pharmaceutical business for decades.”
Activaero currently has two products on the market: AKITA, a patient-controlled breathing system and Watchhaler, a hand-held delivery system for children.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
